Presentation of the report
This report has been prepared in accordance with the Norwegian Transparency Act (the “Transparency Act”) section 5 and summarizes the policies and procedures in Nattopharma AS (“Nattopharma”) with respect to safeguarding of human rights and decent working conditions and provides information on the imolementation and results of NattoPharma’s due diligence.
View the 2022 Transparency Act Report
Latest news & videos
- MenaQ7®
- Mobility & Joint
- News
- Apr 29, 2025
FSANZ Approves Vitamin K2 for Food for Special Medical Purposes
The Food Standards Australia New Zealand (FSANZ) has officially approved the use of Vitamin...
- Lynside® Nutritional Yeasts
- News
- Wellness & Immune
- Apr 23, 2025
Lynside® Forte Se+ for Skin Protection Against Sun Exposure
Selenium yeast boosts skin defenses against sun damage by fighting oxidative stress, supporting repair,...
- MenaQ7®
- Mobility & Joint
- MyCondro®
- Apr 17, 2025
Successful Vital Nutrients Symposium:
Shaping the Future of Healthy Aging
The Vital Nutrients Symposium 2025, held in Kassel, Germany, offered an excellent platform to...
